US FDA to tighten coronavirus vaccine authorization standards ahead of election – Reuters
|Reuters has reported on the US Food and Drug Administration that is expected to soon announce new, more stringent standards for an emergency authorization of a COVID-19 vaccine.
The article explained that lowering the chances that one might be cleared for use before the Nov. 3 election.
Reuters was acknowlding the Washington Post reporting this on Tuesday.
The agency is issuing the guidance to boost transparency and public trust as health experts have become increasingly concerned that the Trump administration might be interfering in the approval process, the newspaper said.
According to the report, the FDA is expected to ask vaccine manufacturers seeking an emergency authorization to follow trial participants for a median of at least two months after they receive a second vaccine shot.
It also said the agency is asking that trials identify a specific number of severe cases of COVID-19 in patients who received a placebo in the trials.
Market implications
US stocks are dependent on vaccine sentiment and stimulus.
The stalemate in Congress over the size and shape of another coronavirus-response bill will continue to dent hopes of a swift economic recovery and weigh on stocks.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.